AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer ...

AstraZeneca PLCAZN0.66%increase; green up pointing triangle said its breast cancer drug Enhertu significantly reduced the risk of dying or disease progression in women with advanced disease in a ...

AstraZeneca (NASDAQ:AZN) and partner Daiichi Sanyko (OTCPK:DSKYF)(OTCPK:DSNKY) said the FDA has accepted their application with priority review for expanded approval of Enhertu for the treatment ...

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic ...

Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications ...

The FDA has said AstraZeneca and Daiichi Sankyo’s Enhertu could be a breakthrough in a potential new lung cancer niche, the second time in the space of a week that the drug has received ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a potential "inflection point" for the company. President Donald Trump is ...

(RTTNews) - Enhertu or fam-trastuzumab deruxtecan-nxki has been granted two additional Breakthrough Therapy Designations in the U.S. for the treatment of adult patients with unresectable or ...

By then, AstraZeneca and cancer drug partner Daiichi Sankyo had already validated the blockbuster potential of HER2-directed ADCs with Enhertu. But Eisai identified BB-1701 as a potential best-in ...

(RTTNews) - Daiichi Sankyo and AstraZeneca's (AZN, AZN.L) Enhertu has been granted Breakthrough Therapy Designation in the U.S. for the treatment of adult patients with unresectable or metastatic ...